| Identification | |
| Name: | Ibandronic acid |
| Synonyms: | Phosphonicacid, [1-hydroxy-3-(methylpentylamino)propylidene]bis- (9CI);BPH 24;Ibandronate;[1-Hydroxy-3-(methylpentylamino)propylidene]diphosphonic acid; |
| CAS: | 114084-78-5 |
| Molecular Formula: | C9H23NO7P2 |
| Molecular Weight: | 319.228942 |
| InChI: | InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17) |
| Molecular Structure: | ![(C9H23NO7P2) Phosphonicacid, [1-hydroxy-3-(methylpentylamino)propylidene]bis- (9CI);BPH 24;Ibandronate;[1-Hydroxy...](https://img.guidechem.com/casimg/114084-78-5.gif) |
| Properties | |
| Transport: | HAZARD |
| Melting Point: | 113-115ºC |
| Flash Point: | 309.3 ºC |
| Boiling Point: | 587.8ºC at 760 mm |
| Density: | 1.449 g/cm3 |
| Refractive index: | 1.537 |
| Water Solubility: | Soluble (insoluble in alcohols, organic solvents) |
| Solubility: | Soluble (insoluble in alcohols, organic solvents) |
| Appearance: | white semi-solid |
| Specification: |
Indications of Ibandronic acid (CAS NO.114084-78-5): Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. Men should not take ibandronate unless they are participating in clinical trials. In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily, 2.50 mg dose treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial of 2,946 women suffering post-menopausal osteoporosis. The participants received either a placebo or an oral ibandronate dose (2.50 mg), or intermittently (20 mg every second day in 12 doses at the beginning of each 3-month interval). Every participant also received daily oral doses of 500 mg of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 per cent when compared to the effects of the placebo drug. |
| Flash Point: | 309.3 ºC |
| Usage: | A biphosphonate bone resorption inhibitor. |
| Safety Data | |
| Hazard Symbols | |
 |
|
